Clinical Trials Logo

Clinical Trial Summary

The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.


Clinical Trial Description

This open prospective observational study will include patients with mild hypercortisolism of both adrenal and pituitary origin not candidate for surgery. Patients taking metyrapone since less than a week will be followed up for 24 weeks. During this period of time, patients will be re-evaluated as far as blood pressure control, glycometabolic control, thrombotic risk parameters, lipid profile, bone turnover markers and cortisol circadian rhythm is concerned. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05255900
Study type Observational
Source Istituto Auxologico Italiano
Contact Chiodini Chiodini, Professor
Phone 02619112506
Email i.chiodini@auxologico.it
Status Recruiting
Phase
Start date April 28, 2022
Completion date February 2024

See also
  Status Clinical Trial Phase
Terminated NCT03379363 - Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Recruiting NCT04045015 - Liquorice and Salivary Cortisol N/A
Recruiting NCT06430528 - A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Recruiting NCT05772169 - Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) Phase 4
Recruiting NCT05368090 - Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism N/A
Not yet recruiting NCT06246357 - Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism Phase 2
Not yet recruiting NCT04433819 - Nailfold Capillaroscopy Evaluation in Cushing Syndrome Patients
Active, not recruiting NCT04308590 - Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Phase 3
Recruiting NCT04127552 - Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations
Completed NCT02335996 - Hypercortisolism and Epicardial Adipose Tissue N/A
Recruiting NCT05766085 - Cortisol Secretion, Sensitivity and Activity and Hypertension